VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RKDA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RKDAArcadia Biosciences, Inc.
$0.69$1M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksRKDABalance Sheet

Arcadia Biosciences, Inc. (RKDA) Balance Sheet

14Y historyFree accessUpdated daily

The company's financial position is increasingly precarious, with total assets shrinking from $19.7 million in 2023Q4 to $5.3 million in 2026Q1, reflecting significant balance sheet erosion.

RKDA Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total Current Assets5.17M6.36M9.24M14.97M25.4M35.39M31.7M28.44M22.88M15.05M52.22M52.02M18.7M4.57M7.88M
Cash & Short-Term Investments3.72M4.56M4.24M11.64M20.64M28.68M25.67M25.33M21.82M13.02M50.56M50.24M16.57M2.83M5.35M
Cash Only954K259K4.24M6.52M20.64M28.68M14.04M8.42M12M9.13M2.01M23.97M16.57M2.83M5.35M
Short-Term Investments2.77M4.3M05.12M0011.63M16.91M9.82M3.9M48.55M26.27M000
Accounts Receivable425K425K1.18M514K1.22M1.37M1.41M602K168K1.24M533K788K1.42M1.02M1.24M
Days Sales Outstanding56.4831.9385.0142.1260.0873.7563.88187.9641.89111.9761.0253.1374.3457.764.3
Inventory840K1.21M904K1.96M2.32M4.43M3.81M1.79M181K229K252K294K424K450K898K
Days Inventory Outstanding146.32142.8111.36328.74138.86185.81267.62739.999.95295.35102.77120.377.5244.06360.58
Other Current Assets184K156K1.99M858K1.21M000000000398K
Total Non-Current Assets154K190K4.28M4.73M3.52M8.53M15.65M4.13M1.15M1.52M4.35M22.23M6.19M4.97M5.48M
Property, Plant & Equipment08K178K1.18M2.53M5.37M9.37M3.76M395K299K508K585K728K941K1.13M
Fixed Asset Turnover475.80x607.25x28.34x3.79x2.93x1.26x0.86x0.31x3.71x13.46x6.28x9.25x9.59x6.88x6.23x
Goodwill000000408K00000000
Intangible Assets39K39K39K39K40K484K370K00000000
Long-Term Investments00000000002.5M19.75M500K1.43M2.77M
Other Non-Current Assets115K143K4.06M3.52M956K2.67M5.51M372K753K1.22M1.35M1.89M4.97M2.6M1.58M
Total Assets5.32M6.55M13.52M19.7M28.92M43.92M47.35M32.57M24.02M16.57M56.57M74.24M24.89M9.54M13.36M
Asset Turnover0.67x0.74x0.37x0.23x0.26x0.15x0.17x0.04x0.06x0.24x0.06x0.07x0.28x0.68x0.52x
Asset Growth %-209.43%-51.57%-31.4%-31.87%-34.15%-7.24%45.36%35.59%44.98%-70.71%-23.8%198.29%160.84%-28.57%-
Total Current Liabilities1.36M2.06M2.56M3.59M4.21M5.04M6.31M5.71M3.05M3.52M3.13M3.45M11.27M9.54M3.36M
Accounts Payable1.1M1.45M703K801K905K1.41M726K492K285K366K222K424K244K220K137K
Days Payables Outstanding179.4171.1986.6134.4854.1459.1450.97202.92157.38472.0590.54173.544.6119.3255.01
Short-Term Debt0000001.14M24K00005.61M4.57M0
Deferred Revenue (Current)0000008K42K96K1M740K1.01M830K1.07M1.16M
Other Current Liabilities263K606K483K634K296K264K263K306K1.58M88K197K02.44M2.29M140K
Current Ratio3.79x3.09x3.61x4.17x6.03x7.02x5.02x4.98x7.49x4.27x16.69x15.08x1.66x0.48x2.35x
Quick Ratio3.17x2.50x3.25x3.63x5.48x6.14x4.42x4.67x7.43x4.20x16.61x14.99x1.62x0.43x2.08x
Cash Conversion Cycle23.43.54109.77236.37144.79200.42280.53724.95-15.54-64.7373.26-0.07107.24182.44369.88
Total Non-Current Liabilities1.07M347K4.73M3.41M3.81M7.68M12.48M18.54M8.15M5.04M31.25M30.57M15.51M17.3M15.69M
Long-Term Debt0000002.1M107K0025.13M24.93M8.87M9.92M8M
Capital Lease Obligations000155K1.01M2.22M5.39M1.5M0000000
Deferred Tax Liabilities000000000000000
Other Non-Current Liabilities1.07M347K4.73M3.26M2.81M5.46M4.99M16.94M8.15M3M3M3M3M3M3M
Total Liabilities2.44M2.41M7.29M7M8.02M12.72M18.8M24.25M11.21M8.56M34.38M34.02M26.77M26.84M19.04M
Total Debt00155K1.01M2.02M3.29M9.35M2.24M0025.13M24.93M14.47M14.56M8M
Net Debt-954K-259K-4.09M-5.51M-18.63M-25.39M-4.69M-6.18M-12M-9.13M23.11M957K-2.1M11.73M2.65M
Debt / Equity0.00x-0.02x0.08x0.10x0.11x0.33x0.27x--1.13x0.62x---
Debt / EBITDA-0.00x--------------
Net Debt / EBITDA0.10x--------------
Interest Coverage------1437.75x-129.85x-5773.20x-5.27x-19.99x-13.86x-5.75x-11.30x-16.87x-54.42x
Total Equity2.88M4.14M6.22M12.7M20.9M31.2M28.55M8.33M12.81M8.01M22.2M40.23M-1.89M-17.3M-5.68M
Equity Growth %-208.25%-33.47%-51.01%-39.22%-33%9.26%242.93%-35.03%60.05%-63.93%-44.82%2233.95%89.1%-204.31%-
Book Value per Share2.113.034.5610.2734.8758.64114.6852.34136.10148.54400.271126.81-182.90-1684.88-102.40
Total Shareholders' Equity2.88M4.14M6.22M12.84M21.03M31.09M27.73M7.71M12.81M8.01M22.2M40.23M-1.89M-17.3M-5.68M
Common Stock66K65K65K65K65K63K54K49K45K42K44K44K000
Retained Earnings-285.6M-281.22M-278.88M-271.84M-257.86M-226.49M-211.82M-207.17M-178.37M-167.26M-151.55M-131.93M-113.97M-95.63M-82.44M
Treasury Stock000000000000000
Accumulated OCI000101K0001K-4.8M-1K-19K-115K000
Minority Interest000-138K-133K103K827K621K0000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and insolvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Rapid Asset Base Erosion Observed

As reported in recent financial filings, RKDA's total assets have contracted from $19.7 million in 2023Q4 to just $5.3 million by 2026Q1, signaling a rapid liquidation of the balance sheet as the company attempts to pivot its business model while facing persistent operational losses.

The consistent decline in total assets suggests that the company is consuming its resource base to fund ongoing operations rather than investing in growth. This trajectory implies that the firm's ability to sustain its current intellectual property development is increasingly compromised without external capital infusion.

Critical Cash Runway Exhaustion Imminent

Based on the company's 2025Q4 reported figures, cash and equivalents plummeted to a precarious $259,000, which represents a significant reduction from the $6.5 million held in 2023Q4, highlighting an urgent liquidity crisis that threatens the firm's ability to meet near-term obligations.

While the current ratio remains above 3.0, this metric is misleading given the absolute scarcity of liquid assets relative to the company's historical burn rate. Investors should monitor this closely, as the current cash position appears insufficient to support even a single quarter of standard operating expenses.

Accumulated Deficit Erodes Shareholder Value

According to quarterly balance sheet data, RKDA's retained earnings have deepened to a deficit of $285.6 million as of 2026Q1, reflecting years of value-destroying operations that have consistently depleted the company's equity base and necessitated repeated strategic pivots.

The persistent growth of the accumulated deficit indicates that the company has failed to achieve a return on invested capital that exceeds its cost of operations. This trend suggests that equity holders are facing significant dilution risk as the firm likely seeks to recapitalize its balance sheet.

Intangible Asset Value Remains Opaque

As indicated by the company's financial statements, goodwill remains stagnant at $39,000, which may suggest that the firm's core intellectual property is not being adequately reflected on the balance sheet, potentially masking the true value or impairment risk of its remaining patent portfolio.

The lack of movement in intangible assets despite the company's pivot to a licensing model warrants further investigation into whether these assets are being properly valued. If the IP holds latent value, it is currently not translating into the tangible liquidity required to sustain the business.

RKDA — Frequently Asked Questions

Quick answers to the most common questions about buying RKDA stock.

What are the total assets of Arcadia Biosciences, Inc. (RKDA)?

As of 2025, Arcadia Biosciences, Inc. (RKDA) had total assets of $6.5M including $6.4M in current assets.

How much debt does Arcadia Biosciences, Inc. (RKDA) have?

Arcadia Biosciences, Inc. (RKDA) carries total debt of $0.0M, offset by $4.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Arcadia Biosciences, Inc.?

Arcadia Biosciences, Inc. (RKDA) has total shareholders' equity (book value) of $4.1M ($3.03 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Arcadia Biosciences, Inc.'s current ratio and liquidity?

Arcadia Biosciences, Inc. (RKDA) reported a current ratio of 3.09x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.